Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus STAXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus STAXYN.
ATMEKSI vs STAXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
1.5 mg/kg IV every 4 weeks
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor